Meeting Coverage

Meeting Coverage

Is Luspatercept a New Option for Patients With MDS?

Dr. List discusses results from the MEDALIST trial in patients with transfusion-dependent myelodysplastic syndromes, which were presented as a plenary abstract at the 2018...

Ibrutinib Outperforms Chemoimmunotherapy in CLL

Dr. Woyach shares findings from her plenary abstract, in which ibrutinib improved survival outcomes in older patients with chronic lymphocytic leukemia, compared with a...

Four or Six Cycles of CHOP in Younger DLBCL Patients?

Viola Poeschel, MD, discusses results from the Flyer trial, which showed that younger, fit patients with diffuse large B-cell lymphoma can be treated with...

AMG 330 Takes a BiTE out of Relapsed/Refractory AML

Farhad Ravandi-Kashani, MD, discusses results from the first-in-human trial showing the bispecific T-cell engager antibody was tolerable in patients with previously treated acute myeloid leukemia.
video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
video

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...
video

Does Blinatumomab Affect CAR T-Cell Therapy Response?

In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...
video

Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment

Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory...
video

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.